Market giddy on preliminary results of Tarceva, but all the data is not in yet...OSI Pharmaceuticals (OSIP) announced today that its Phase III trial of Tarceva met its primary and secondary endpoints. Tarceva is the first drug of its kind to demonstrate prolonged survival in patients with relapsed non-small cell lung cancer (NSCLC). The trial also showed improved time to symptomatic deterioration, progression-free survival and response rate.
